TRAVERE THERAPEUTICS INC. - COMMON STOCK

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 9 2024 14:00:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference

10 9 2024 13:01:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

05 9 2024 14:34:13 提供 Nasdaq GlobeNewswire

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024

22 8 2024 13:30:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

06 8 2024 13:30:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics Reports Second Quarter 2024 Financial Results

01 8 2024 13:01:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics to Report Second Quarter 2024 Financial Results

25 7 2024 13:30:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

08 7 2024 13:30:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 6 2024 14:00:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

15 5 2024 14:00:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress

09 5 2024 13:30:56 提供 Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

08 5 2024 13:30:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics Reports First Quarter 2024 Financial Results

06 5 2024 13:01:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics to Report First Quarter 2024 Financial Results

29 4 2024 13:30:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

24 4 2024 04:05:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International

04 4 2024 13:30:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association

03 4 2024 13:30:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 3 2024 14:00:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)

11 3 2024 04:05:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

26 2 2024 13:30:00 提供 Nasdaq GlobeNewswire